pronounced increase in the serum fibrin/fibrinogen degradation products suggested either intravascular coagulation or excessive fibrinolysis. The latter, however, could be excluded by the-normal plasma plasminogen and the prolonged euglobulin clot lysis time. Intravascular coagulation was subsequently confirmed by the renal biopsy. Although it is likely that the intravascular coagulation caused the tubular necrosis and renal failure in this patient the pathogenesis of the fibrin deposition must remain speculative. Catovsky et al. (1970) drew attention to the frequency of thromboembolic disorders in myelomatosis, and Preston and Lee (1972) Journal, 1972, 1, 605 Benzhexol is a synthetic antiparkinsonian drug with peripheral and central atropine-like effects (Goodman and Gilman, 197d ), thus its use in patients with angle-closure glaucoma is contraindicated. We have not found any report in the literature of blindness due to angle-closure glaucoma induced by this drug. Three such cases are reported here.
Case Reports Case 1.-A 57-year-old man suffering from Parkinson's disease and senile dementia was examined in the eye clinic in December 1965. He had been receiving 15 mg of benzhexol daily for two years. In the right eye the visual acuity was 6/15 and the intraocular pressure was maximal. The cornea was slightly oedematous and the pupil was 4 mm in diameter and did not react to light. There was excavation and atrophy of the optic disc. The visual field was constricted to 5-10' around the centre. In the left eye the visual acuity was 6/15, the intraocular pressure was 50 mm Hg, the cornea was slightly oedematous, and the fundus was normal. The visual field was intact. On gonioscopy the anterior chamber angle seemed closed in both eyes. The administration of benzhexol was stopped, pilocarpine and eserine were instilled every 5 minutes, acetazolamide was given intravenously, and glycerol was administered by mouth. The intraocular pressure in the left eye became normal and the angle opened. In the right eye the intraocular pressure remained high and a filtering iridectomy was performed. Subsequently a peripheral iridectomy was performed in the left eye.
Case 2.-A 70-year-old man suffering from Parkinson's disease and senile dementia was examined in the clinic in March 1966. He had been receiving 15 mg of benzhexol daily for one year. After four months on this medication he had complained of deterioration of vision in the right eye and two months later glaucoma was discovered. When first seen by us the right eye had no light perception because of absolute glaucoma and there was advanced excavation and atrophy of the optic disc. In the left eye vision was 6/9, the intraocular pressure was 64 mm Hg, and there was slight excavation of the optic disc. The visual field was normal. In both eyes the Case 3.-A 55-year-old woman was admitted to the clinic in July 1970 because of high introcular pressure in both eyes first discovered earlier the same day. She had been receiving 15 mg of benzhexol daily for two years because of paranoia. On examination the right eye was found to be blind from glaucoma. In the left eye vision was 6/9, the intraocular pressure was 43 mm Hg, and the fundus was normal. No glaucomatous field defects were present. The angle was closed in both eyes. Benzhexol medication was stopped and she was treated with miotics and acetazolamide. In the left eye the intraocular pressure became normal and the angle opened. A peripheral iridectomy was performed. In the right, blind eye the intraocular pressure remained high.
Comment
Total blindness of one eye in two patients and practical blindness with tubular vision in one eye of a third patient occurred as a result of angle-closure glaucoma due to long-term treatment with benzhexol. Glaucoma induced by the systemic administration-of atropine has been described by several authors (Ulman and Mossman, 1950; Larmande and Toulant, 1951; Duke-Elder, 1969) as a result of subcutaneous injection, suppositories, or during prolonged administration of belladonna by mouth.
Benzhexol has a mydriatic effect which is about one-third as strong as that of an equal dose of atropine systemically (Goodman and Gilman, 1970) . Since the therapeutic dosage of benzhexol in Parkinson's disease is from 15 to 30 mg a day its mydriatic effect is many times greater than that obtained through therapeutic use of atropine, which seldom exceeds 2 mg a day. The prolonged cumulative effect of benzhexol tends to cause creeping angle-closure glaucoma-that is, glaucoma without acute symptoms of pain and redness of the eye. This and the mental condition of the present patients account for the delay in the diagnosis of the glaucoma. It is therefore advisable to have gonioscope evaluation in all patients who are to be treated with benzhexol or any related drug.
